CBA
PTGX icon

Coastal Bridge Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Coastal Bridge Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,400
Closed -$254K – 209
2021
Q4 		$254K Buy
+7,400
New +$234K 0.05% 162

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Coastal Bridge Advisors's PTGX Position: Q1 2022 in Review

Coastal Bridge Advisors sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 7,400 shares — an estimated $254K sold.

Coastal Bridge Advisors first reported a position in PTGX in Q4 2021 and held it in 1 quarter. The position peaked at $254K in Q4 2021. 140 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

  • Coastal Bridge Advisors reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Coastal Bridge Advisors sold 7,400 Protagonist Therapeutics shares in Q1 2022, an estimated $254K.
  • Coastal Bridge Advisors first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 1 quarter.
  • Coastal Bridge Advisors's Protagonist Therapeutics position peaked at $254K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Coastal Bridge Advisors's 13F filing for Q1 2022, filed 13 May 2022.